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Mukta Arora1,2 for the Chronic Leukemia Working CommitteeUnrelated donor (URD) hematopoietic cell transplantation (HCT) can eradicate chronic myelogenous leuke-
mia (CML). It has been postulated that greater donor–recipient histoincompatibility can augment the graft-
versus-leukemia (GVL) effect. We previously reported similar, but not equivalent, outcomes of URD versus
sibling donor HCT for CML using an older, less precise classification of HLA matching. Here, we used our
recently refined HLA-matching classification, which is suitable for interpretation when complete allele-level
typing is unavailable, to reanalyze outcomes of previous HCT for CML. We found that using our new matching
criteria identifies substantially more frequent mismatching than older, less precise ‘‘6 of 6 antigen–matched’’
URD-HCT. Under the new criteria, only 37% of those previously deemed ‘‘HLA- matched’’ were HLA well
matched, and 44% were partially matched. Using our refined matching criteria confirms the greater risk
of graft failure in partially matched or mismatched URD–recipient pairs compared with either sibling or
well-matched URD–recipient pairs. Acute and chronic graft-versus-host disease (aGVHD, cGVHD) are sig-
nificantly more frequent with all levels of recategorized URD HLA matching. Importantly, overall survival
(OS) and leukemia-free survival (LFS) remain significantly worse after URD-HCT at any matching level. No
augmented GVL effect accompanied URD HLA mismatch. Compared with sibling donor transplants, we
observed only marginally increased (not statistically significant) risks of relapse in well-matched, partially
matched, and mismatched URD-HCT. These data confirm the applicability of revised HLA-matching scheme
in analyzing retrospective data sets when fully informative, allele-level typing is unavailable. In this analysis,
greater histoincompatibility can augment GVHD, but does not improve protection against relapse; thus the
best donor remains the most closely matched donor.
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previously reported similar, but not equivalent, out-
comes of 2464 URD HCTs and 450 sibling donor
HCTs for treatment of chronic myelogenous leukemia
(CML) [1]. We noted that HCT using an URD en-
tailed a 7% to 10% poorer 5-year survival and slightly
higher rates of graft-versus-host disease (GVHD) and
treatment-related mortality (TRM), but conferred no
greater protection against relapse. In that analysis,
HLA matching used an outdated definition; interme-
diate-resolution matching at HLA-A and -B (class I)
and allele-level matching at HLA-DRB1 (class II)
[1]. Whereas refined HLA-typing techniques have
confirmed that allele typing at HLA-A, -B, -C, and
-DRB1 may all contribute to better posttransplanta-
tion outcomes [2-4], whether HLA mismatch between
URDs and recipients can confer better protection
against relapse remains uncertain.
The Center for International Blood and Marrow
Transplant Research (CIBMTR) recently compared
allele-level typing of 3514 HLA-identical siblings and
1052 HLA-matched and partially matched URD
HCT recipients, all with chronic-phase CML [5].
Allele-level mismatching at 4 HLA loci (HLA-A, -B,
-C, and -DR, but not -DQ) identified greater risks of
GVHD, TRM, and overall mortality, but conferred no
greater protection against relapse compared with even
a single allele mismatch between donor and recipient.
In the observational databases at the National Mar-
row Donor Program (NMDP) and CIBMTR, donor–
recipient matching often is incomplete, commonly
missing HLA-C typing data and class I allele-level
typing. We recently described an HLA classification
scheme able to categorize the quality of donor–recipient
HLA matching based on the number of loci examined
and the resolution of typing at each locus [6]. We
identified 3 levels of donor–recipient matching: well
matched, with no defined mismatches and no untested
HLA locus; partially matched, with only 1 untested or
mismatched locus; and mismatched, with 2 or more
known or mismatched or untested HLA loci. This new
HLA matching scheme allows prediction of outcome
even if donor–recipient pairs are incompletely typed,
not at all 4 pertinent HLA-A, -B, -C, or -DR loci [6].
To assess the impact of HLA mismatch on out-
come, as well as its association with any augmented
GVL effect, we reanalyzed our previous sibling and
URD cohort [1] according to our new HLA-matching
scheme [6]. Here we report our outcomes and compare
them with those reported recently for complete allele-
level HLA typing in a different validation cohort [5].PATIENTS AND METHODS
All patients had CML and underwent allogeneic
HCT from an URD (n5 2464) between 1988 and1999. Data were reported to the NMDP using prospec-
tively designed data-capture methods, auditing, cen-
tralized compilation, and data error correction [1].
Data from sibling donors (n5 450) at 34 participating
centers from 1991 to 1999 were obtained using the
same data-capture methods. Adjusted probabilities of
overall survival (OS) and leukemia-free survival (LFS)
were estimated using the Cox proportional hazards re-
gression model [7]. Multivariate models were built us-
ing a stepwise forward selection technique, with a P
value of# .05 as the criterion for inclusion in the final
model. The transplantation center was included as
a fixed effect in the regression model.RESULTS
The study population has been described previ-
ously [1]. Most sibling donor (63%) and URD recipi-
ents (59%) were male; their median age was 39 and 36
years, respectively. Most recipients were in the first
chronic phase (sibling, 82%; URD 67%) and were
a median of 7 and 17 months from diagnosis, respec-
tively; 86% and 83% had a pre-HCT performance
score of 90 to 100. Myeloablative (MA) pre-HCT con-
ditioning included total body irradiation (TBI) along
with cyclophosphamide (Cy) in 2340 cases (287 sibling
and 2053 URD). Others received chemotherapy-only
conditioning (without TBI), most often busulfan
(Bu) 1 Cy. As shown in Table 1, 450 HLA genotypi-
cally identical sibling donors were contrasted with
2464 URDs originally categorized as HLA matched
(reflecting ‘‘6 antigen matching’’: intermediate-resolu-
tion matching at HLA-A and -B and allele matching at
HLA-DRB1) or HLA partially matched [1]. Only 805
(32.8%) were included in the allele-level matching
GVL report [5]. Based on our new criteria, these
URDs are recategorized into well matched, partially
matched, and mismatched. As shown in Table 1, 667
of the 1797 donor–recipient pairs (37%) originally
deemed HLA matched are reclassified as HLA well
matched under the new classification scheme. How-
ever, of the pairs originally deemed HLA matched,
783 (44%) are now classified as HLA partially
matched, and 347 (19%) are classified as HLA mis-
matched. Of the previously classified 667 mismatched
URD–recipient pairs, only 14 (2%) are now classified
as well matched; 109 (16%) are classified as partially
matched, and 544 (82%) are classified as mismatched.
Using our refined matching classification scheme
leads us to modify the conclusions of our earlier report.
In the original analysis, graft failure was significantly
more frequent after both matched and partially
matched URD HCT compared with HLA-identical
sibling HCT (Table 2). After reclassification, only par-
tially matched or mismatched URD–recipient pairs
have a significantly greater risk of graft failure. Acute
Table 1. Reclassification of HLAMatching in Matched Sibling
Donor HCT (n5 450) and URD HCT (n5 2464)
Donor–Recipient HLA Matching
Revised Classification Scheme
HLA-Matched
(Original 6/6)
Partially Matched
(Original not 6/6)
Related HLA identical 450 (100%) –
Unrelated well matched 667 (37%) 14 (2%)
Unrelated partially matched 783 (44%) 109 (16%)
Unrelated mismatched 347 (19%) 544 (82%)
HCT indicates hematopoietic cell transplantation; URD, unrelated
donor.
Originally, URD HCT included matched (6/6 matching; n5 1797) or
partially matched (not 6/6; n5 667) HCT. These are now reclassified,
indicating that only 37% of those originally classified as URD matched
are well matched, whereas 2% of originally classified as partially matched
are now well matched.
Table 2. Multivariate Analysis: Original versus Revised HLA
Classification
OR/HR (95% CI)* P
Graft failure
Related HLA identical 1.0 –
URD matched (original 6/6) 5.39 (1.92-15.15) .0014
URD partially
matched (original not 6/6)
11.81 (4.12-33.83) <.0001
Unrelated well matched 2.26 (0.71-7.18) .16
Unrelated partially matched 6.83 (2.38-19.65) .0004
Unrelated mismatched 12.20 (4.30-34.61) <.0001
Acute GVHD grade II/IV
Related HLA identical 1.0 –
URD matched (original 6/6) 1.56 (1.32-1.84) <.0001
URD partially
matched (original not 6/6)
1.91 (1.57-2.31) <.0001
Unrelated well matched 1.48 (1.23-1.78) <.0001
Unrelated partially matched 1.60 (1.33-1.92) <.0001
Unrelated mismatched 1.85 (1.54-2.22) <.0001
Chronic GVHD
Related HLA identical 1.0 –
URD matched (original 6/6) 1.48 (1.26-1.74) <.0001
URD partially
matched (original not 6/6)
1.50 (1.22-1.84) .0001
Unrelated well matched 1.54 (1.29-1.85) <.0001
Unrelated partially Matched 1.45 (1.20-1.75) <.0001
Unrelated mismatched 1.46 (1.20-1.77) .0001
Survival
Related HLA identical 1.0 –
URD matched (original 6/6) 1.89 (1.59-2.25) <.0001
URD partially
matched (original not 6/6)
2.74 (2.25-3.35) .0001
Unrelated well matched 1.57 (1.30-1.90) <.0001
Unrelated partially matched 1.99 (1.65-2.40) <.0001
Unrelated mismatched 2.77 (2.30-3.36) .0001
Disease-free survival
Related HLA identical 1.0 –
URD matched (original 6/6) 1.82 (1.53-2.16) <.0001
URD partially
matched (original not 6/6)
2.66 (2.18-3.25) <.0001
Unrelated well matched 1.54 (1.27-1.86) <.0001
Unrelated partially matched 1.92 (1.59-2.32) <.0001
Unrelated mismatched 2.70 (2.24-3.27) <.0001
Relapse
Related HLA identical 1.0 –
URD matched (original 6/6) 1.13 (0.77-1.64) .53
URD partially
matched (original not 6/6)
1.48 (0.95-2.30) .09
Unrelated well matched 0.97 (0.63-1.48) .86
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significantly more frequent in both matched and par-
tially matched URD HCT, remain significantly more
frequent in all 3 URD groups. Chronic GVHD
(cGVHD) remains significantly more frequent in all
3 groups and the hazard ratios are close to those re-
ported originally. Importantly, OS and disease-free
survival (DFS) remain significantly worse in URD
HCT at any matching level using either the older, im-
precise HLA classification scheme or the newer, more
refined scheme.
We originally reported that hematologic relapse
was unaffected by donor–recipient histoincompatibil-
ity. We detected no increase in GVL associated with di-
minished HLA compatibility, despite an increased
incidence of both aGVHD and cGVHD. In the present
analysis, compared with matched sibling donor HCT,
the risk of leukemia relapse was marginally increased
(but not statistically significantly so) in the URD
HLA-matching cohorts. Not surprisingly, in the mul-
tivariate analysis, advanced-phase disease, older recip-
ient age, and transplant from a male donor were
associated with more frequent relapse (not shown).Unrelated partially matched 1.32 (0.86-2.01) .20
Unrelated mismatched 1.43 (0.94-2.19) .09
URD indicates unrelated donor; GVHD, graft-versus-host disease.
*Multivariate regression results are given as hazard ratios (HRs), with
95% confidence intervals (CIs) for different HLA matching in Cox model
analysis of endpoints indicated; logistic regression results are given as
odds ratios (OR), with 95% CIs, for graft failure. Compared with
HLA-identical related donors, the original URD HLA analysis results
are contrasted with the revised HLA classification for URD matching.
The analysis is adjusted for other significant covariates, including age,
sex, and CMV status, disease status (accelerated or blast phase), time
to transplantation beyond 1 year, and interferon therapy pre-HCT.DISCUSSION
Our findings confirm the clinical utility of our
revised HLA-matching classification scheme even
when incomplete or only intermediate-resolution
HLA typing is available. The data identify substantial
misclassification in the less-precise and outdated ‘‘6 of
6 matching’’ terminology and confirms the validity of
our revised HLA classification scheme in predicting
graft failure, GVHD, survival, DFS, and leukemia re-
lapse. Using this scheme, we observe findings similar
to those reported using fully informative allele-level
typing; even modest HLA allele-level differences ad-
versely affect survival. Although we emphasize that
complete allele-level typing at HLA-A, -B, -C, and
-DR is most useful for URD selection before HCT,
this refined HLA classification scheme also can beused in retrospective analyses to predict outcome and
assess the clinical importance of histoincompatibility
even when complete HLA typing is unavailable. We
also note that, despite hopes or assertions to the con-
trary, incomplete HLA matching does not augment
GVL, at least for patients with CML. We can specu-
late about the differences that we might find if we
were to analyze HCT using reduced-intensity
1478 Biol Blood Marrow Transplant 15:1475-1478, 2009D. J. Weisdorf et al.conditioning (RIC) or only imatinib-resistant patients,
or even whether the immunosuppression required to
control mismatch-associated GVHD might limit the
impact of the observed GVL. However, the available
data suggest that even in an era when HCT is reserved
for patients failing tyrosine kinase inhibitor therapy
[8], the best donor is still the most closely HLA-
matched donor, to help limit peritransplantation mor-
bidity and provide a potent GVL effect.ACKNOWLEDGMENTS
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